Glenmark Pharmaceuticals Inc., USA has announced the launch of Milnacipran Hydrochloride Tablets across four dosage strengths, marking another significant addition to the company's generic pharmaceutical portfolio in the North American market.

Product Launch Details

The US subsidiary launched Milnacipran Hydrochloride Tablets as an authorized generic to Savella® Tablets across multiple dosage strengths. The product specifications and market positioning are outlined below:

Market Opportunity

According to IQVIA sales data for the 12-month period ending January 2026, the Savella® Tablets market achieved substantial annual sales figures:

Management Commentary

Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about the launch, stating that the company is excited to announce the launch of Milnacipran Hydrochloride Tablets as the authorized generic to Savella® Tablets. He emphasized that this launch further strengthens the company's commitment to bring quality and affordable alternatives for patients to the market.

Product Specifications and Compliance

The launched product adheres to specific regulatory requirements and indications. Glenmark's Milnacipran Hydrochloride Tablets is approved only for the indications listed in Glenmark's approved label. The company has clarified that while IQVIA data obtained covers all approved reference listed drug indications, Glenmark's product is specifically approved for the indications listed in its approved label and is not marketed for all reference listed drug indications.

Strategic Significance

This launch represents Glenmark's continued expansion in the US generic pharmaceutical market, providing healthcare providers and patients with additional treatment options. The authorized generic approach allows the company to offer cost-effective alternatives while maintaining quality standards equivalent to the reference brand product.

Glenmark Pharmaceuticals Limited has secured a significant regulatory milestone with the United States Food & Drug Administration (U.S. FDA) granting final approval for its Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). This approval positions the company to enter a substantial over-the-counter allergy relief market worth hundreds of millions of dollars.

FDA Approval and Product Details

The FDA has determined that Glenmark's Fluticasone Propionate Nasal Spray USP is bioequivalent to the reference listed drug, Flonase® Allergy Relief Nasal Spray, 50 mcg per spray, manufactured by Haleon US Holding LLC. The product will be distributed in the United States by Glenmark Therapeutics Inc., USA, marking a strategic expansion into the OTC nasal spray segment.

Market Opportunity and Commercial Potential

According to Nielsen® syndicated data for the latest 52-week period ending March 3, 2026, the Flonase® Allergy Relief Nasal Spray market achieved annual sales of approximately $384.7 million. This substantial market size represents a significant commercial opportunity for Glenmark's newly approved product.

The market data includes brand and all available therapeutic equivalents, providing a comprehensive view of the competitive landscape that Glenmark will be entering with its bioequivalent formulation.

Management Commentary and Strategic Significance

Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about the approval, stating: "We are excited to announce the recent approval of Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). As the first approved nasal spray distributed by Glenmark Therapeutics Inc., USA in the OTC space, we look forward to bringing this quality over-the-counter solution to our customers when we launch in April 2026."

This launch represents several strategic milestones for the company:

• First nasal spray product in Glenmark's OTC portfolio in the US market
• Entry into the substantial allergy relief segment
• Expansion of the company's over-the-counter product offerings
• Strengthening of Glenmark Therapeutics Inc., USA's distribution capabilities

Company Profile and Global Presence

Glenmark Pharmaceuticals Ltd. operates as a global, research-led pharmaceutical company with a focus on innovation and accessibility. The company maintains 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and maintains a commercial footprint in over 80 countries.

The company delivers a diversified portfolio across branded, innovative, generics, and consumer health products, with particular focus on respiratory, dermatology, and oncology therapeutic areas. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.